AstraZeneca, Daiichi Sankyo voluntarily withdrawn the MAA in the EU for datopotamab deruxtecan for patients with locally ...
AstraZeneca, a global, science-led biopharmaceutical company, and Daiichi Sankyo have voluntarily withdrawn the marketing authorisation application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally …